Table 1 Clinical characteristics according to cohort
Ochsner Clinic (N = 646) | Bishoff Cohort (N = 416) | ||||
|---|---|---|---|---|---|
Characteristic | N | Median (IQR) or frequency | N | Median (IQR) or frequency | p-value |
Age at diagnosis (years) | 646 | 64 (58, 70) | 416 | 62 (58, 66) | 2.0 × 10−5 |
Ancestry | |||||
African-American | 241 | 37.3% | 67 | 16.1% | 2.8 × 10−14 |
Non African-American | 405 | 62.7% | 349 | 83.9% | |
Pre-biopsy PSA (ng/μL) | 646 | 5.8 (4.5, 8.3) | 416 | 6.0 (4.6, 9.0) | 0.49 |
Biopsy Gleason Scorea | |||||
<7 | 333 | 51.5% | 159 | 54.3% | 3.2 × 10−3 |
3 + 4 = 7 | 156 | 24.1% | 86 | 29.4% | |
4 + 3 = 7 | 61 | 9.4% | 28 | 9.6% | |
>7 | 96 | 14.9% | 28 | 6.8% | |
Clinical T stage | |||||
T1 | 471 | 72.9% | 261 | 62.7% | 1.4 × 10−8 |
T2 | 151 | 23.4% | 154 | 37.0% | |
T3 | 24 | 3.7% | 1 | 0.2% | |
Percent positive cores | 646 | 42.9 (28.6, 66.7) | 416 | 33.3 (20.0, 50.0) | 1.3 × 10−7 |
CAPRA risk category | |||||
Low (0–2) | 288 | 44.6% | 202 | 48.6% | 3.2 × 10−5 |
Intermediate (3–5) | 258 | 39.9% | 187 | 45.0% | |
High (6–10) | 100 | 15.5% | 27 | 6.5% | |
CCP score | 646 | 0.3 (−0.2, 0.9) | 416 | −0.1 (−0.6, 0.5) | 1.5 × 10−12 |
Treatment | |||||
Surgery | 384 | 59.4% | 416 | 100% | <2.2 × 10−16 |
XRT | 262 | 40.6% | 0 | 0% | |
Progression to metastatic disease | |||||
Events | 28 | 4.3% | 7 | 1.7% | <2.2 × 10−16c |
Years to last follow-upb | 646 | 5.5 (4.0, 6.8) | 416 | 7.1 (5.4, 10.0) | |
Events by AUA Risk Categoryd | |||||
Low | 2/285 | 0.7% | 0/189 | 0.0% | n/a |
Intermediate | 9/200 | 4.5% | 4/184 | 2.2% | |
High | 17/161 | 10.6% | 3/43 | 7.0% | |
